Figure 2.
Kaplan-Meier analysis of OS and RFS between the antidiabetic treatment group and no antidiabetic treatment group. (A) Survival analysis demonstrated that patients in the antidiabetic treatment group had longer OS time than patients in the no antidiabetic treatment group (P=0.007). (B) Patients in the antidiabetic treatment group had a better RFS compared to patients with no antidiabetic treatment (P=0.001). OS, overall survival; RFS, recurrence-free survival.